News
Gasping for dollars: Insurance companies take your breath away
www.acsh.org
[American Council on Science and Health] - ACSH's Dr. Josh Bloom doesn't like this trend one bit. “Instead of access to first-line drugs," he observes, "patients might have to first rely on second- or third-line therapies that may very well fail — and only then have a shot at the best drug.
Easing approvals for “breakthroughs” may have consequences
www.acsh.org
[American Council on Science and Health] - In response to this latest proposal, ACSH's Dr. Josh Bloom sees both pros and cons. “Moving efficacy trials to the post-marketing phase would, on the one hand, allow us to have new drugs faster,” he says. “But we will certainly see more problems with
Second chances for obesity drugs?
www.acsh.org
[American Council on Science and Health] - As ACSH's Dr. Josh Bloom points out, “The unusually high burden being placed on weight-loss drugs is no doubt a result of the Fen-Phen debacle of 1997, where the only really effective obesity drug was withdrawn after cases of heart valve damage were
The ugly toll of health 'efficiency'
nypost.com
[New York Post] - By JOSH BLOOM As the Supreme Court hears arguments this week on whether the ObamaCare law is constitutional, here's something to think about — a possible real-life example of what all that “death panel” talk really means. The Advisory Committee on
sorted by relevance / date